According to research by Zeller et al. ovarian cancer patients who undergo platinum-based chemotherapy may develop hypermethylation of the MLH1 gene, resulting in gene inactivation, and poorer clinical outcomes. The gene discussed is MLH1; the disease is ovarian carcinoma.